Oncotype DX Breast Cancer Testing

East Sussex Healthcare NHS Trust · awarded 2 March 2026

£273k Award value £272,700
1 Supplier Recorded as a small or medium-sized business
31 Mar 2027 Runs until from 1 Apr 2026

Who

BuyerEast Sussex Healthcare NHS Trust Saint Leonards-on-sea
Supplier Exact Sciences UK, Ltd.
Categoryservices
ClassificationPathology services CPV 85111800
Notice published3 March 2026

What it is for

Oncotype DX is a validated genomic assay recommended by NICE (DG34) for guiding chemotherapy decisions in specific cohorts of early breast cancer. It provides a Recurrence Score that stratifies patients into groups where chemotherapy is beneficial versus where endocrine therapy alone is sufficient. Additional information: This is a call off contract from framework 2023/S 000-028831 based on previous contracts usage.

Read the original award notice on Contracts Finder →

Other contracts from this buyer

72 awards on file, worth £82.0m.

Everything East Sussex Healthcare NHS Trust has awarded →

Other contracts won by this supplier

5 awards on file, worth £1.3m.

Everything Exact Sciences UK, Ltd. has won →